8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 29, 2016

Exponent, Inc.

(Exact name of registrant as specified in its charter)

Delaware	0-18655	77-0218904
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

149 Commonwealth Drive Menlo Park, CA	94025
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code (650) 326-9400

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 29, 2016, Exponent’s Board of Directors appointed Dr. Catherine Corrigan as its President. Dr. Paul Johnston will continue to serve as the Company’s Chief Executive Officer.

Dr. Corrigan, age 47, joined Exponent in 1996. Dr. Corrigan was promoted to Principal in the Biomechanics practice in 2002. Dr. Corrigan was promoted to Corporate Vice President in 2005 and was appointed Group Vice President in 2012. Dr. Corrigan earned her Ph.D. (1996) in Medical Engineering and Medical Physics and her M.S. (1992) in Mechanical Engineering from the Massachusetts Institute of Technology and her B.S.E. in Bioengineering from the University of Pennsylvania. Prior to joining Exponent, Dr. Corrigan was a researcher in the Orthopedic Biomechanics Laboratory at Beth Israel Hospital and Harvard Medical School.

Upon her appointment as President, Dr. Corrigan’s base salary was set at $550,000 and she received a stock option grant for 24,000 shares. Dr. Corrigan will be relocating from the Company’s Philadelphia, Pennsylvania office to its Menlo Park, California office. In connection with the relocation, the Company agreed to purchase Dr. Corrigan’s primary residence in Pennsylvania for an appraised value of $1.25 million, which it intends to resell, and to reimburse standard relocation expenses as approved by the Company’s Chief Executive Officer.

Item 9.01 Financial Statements and Exhibits

The Press Release included as Exhibit 99.1 of this Current Report on Form 8-K shall be considered “furnished” pursuant to this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed incorporated by reference into any of the Registrant’s reports or filings with the Securities and Exchange Commission, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing.

99.1 Press release announcing executive transition dated July 29, 2016.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

EXPONENT, INC.
By:	/s/ Richard L. Schlenker
Name:	Richard L. Schlenker
Title:	Executive Vice President, Chief Financial Officer, and Corporate Secretary

Date: July 29, 2016

EX-99.1

Exhibit 99.1

Exponent Appoints Dr. Catherine Corrigan to President

MENLO PARK, Calif., July 29, 2016 Exponent, Inc. (Nasdaq:EXPO) announced today the appointment of Dr. Catherine Corrigan to the position of President, reporting to Dr. Paul Johnston, CEO.

Dr. Corrigan joined Exponent’s Philadelphia office in 1996, was promoted to Principal in 2002 and to Corporate Vice President in 2005. She was promoted to Group Vice President to lead the Transportation Group and joined the Company’s Operating Committee in 2012. Dr. Corrigan is relocating to the Menlo Park office.

"Catherine has demonstrated strong leadership as a Group Vice President, and I am confident that she will have a successful transition into managing all of our operating groups.  While Catherine has consulted on issues affecting many industries, her deep experience related to vehicle safety is a valuable asset as Exponent continues to expand its transportation consulting services. She is highly respected by clients and employees for her expertise and leadership. I am excited to partner with Catherine in her new role,” stated Dr. Johnston.

“I am excited to take on this new role,” stated Dr. Catherine Corrigan. “Exponent has exceptional employees and I am eager to work with people across the Company to continue to make this a great place to work. Over the past twenty years, I have seen the Company expand from primarily offering reactive services in engineering to one that offers both proactive and reactive services in engineering, science, regulatory and business consulting. I am confident in our ability to continue to evolve our services as technology changes. Exponent has a bright future,” concluded Dr. Corrigan.

Dr. Corrigan addresses issues involving the biomechanics of human injury, with expertise in the areas of human tolerance, occupant kinematics, and rigid body dynamics. She obtained her Ph.D. in Medical Engineering and Medical Physics and her M.S. in Mechanical Engineering from the Massachusetts Institute of Technology, and her B.S.E. in Bioengineering from the University of Pennsylvania.

About Exponent

Exponent is an engineering and scientific consulting firm providing solutions to complex problems. Exponent's multidisciplinary organization of scientists, physicians, engineers, and business consultants brings together more than 90 technical disciplines to address complicated issues facing industry and government today. The firm has been best known for analyzing accidents and failures to determine their causes, but in recent years it has become more active in assisting clients with human health, environmental and engineering issues associated with new products to help prevent problems in the future.

Exponent may be reached at (888) 656-EXPO, info@exponent.com, or www.exponent.com.

1 

This news release contains, and incorporates by reference, certain "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995, and the rules promulgated pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended) that are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. When used in this document and in the documents incorporated herein by reference, the words “intend,” "anticipate," "believe," "estimate," "expect" and similar expressions, as they relate to the Company or its management, identify such forward-looking statements. Such statements reflect the current views of the Company or its management with respect to future events and are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company's actual results, performance, or achievements could differ materially from those expressed in, or implied by, any such forward-looking statements. Factors that could cause or contribute to such material differences include the possibility that the demand for our services may decline as a result of changes in general and industry specific economic conditions, the timing of engagements for our services, the effects of competitive services and pricing, the absence of backlog related to our business, our ability to attract and retain key employees, the effect of tort reform and government regulation on our business, and liabilities resulting from claims made against us. Additional risks and uncertainties are discussed in our Annual Report on Form 10K under the heading "Risk Factors" and elsewhere in the report. The inclusion of such forward-looking information should not be regarded as a representation by the Company or any other person that the future events, plans, or expectations contemplated by the Company will be achieved. The Company undertakes no obligation to release publicly any updates or revisions to any such forward-looking statements.

Source: Exponent, Inc.

2